source
- FDA rejects Summit Therapeutics' lung cancer drug ivonescimab, citing insufficient survival benefitThe U.S. Food and Drug Administration issued a complete response letter rejecting the lung‑cancer therapy ivonescimab, which is being developed by Summit Therapeutics in partnership with Akeso. In…
- AI drugmaker Isomorphic Labs raises $5 billion in Series C roundIsomorphic Labs, an Alphabet spinout that applies artificial intelligence to drug discovery, announced a $5 billion Series C financing. The round was led by Greenoaks and Sequoia Capital, with Alp…